FDA Approves Stiolto Respimat

Stiolto Respimat Generic Name: olodaterol and tiotropium bromideDate of Approval: May 21, 2015Company: Boehringer Ingelheim Pharmaceuticals, Inc. Stiolto Respimat is a combination of the long-acting beta2-adrenergic agonist olodaterol (Striverdi Respimat), and the anticholinergic agent tiotropium (Spiriva Respimat). The U.S. Food and Drug Administration (FDA) has...

Read More

FDA Approves Fycompa as Adjunctive Treatment for Primary Generalized Tonic-Clonic Seizures

Fycompa Generic Name: perampanel (per AM pa nel) Brand Names: Fycompa What is Fycompa? Fycompa (perampanel) is an anticonvulsant used to treat seizures.Fycompa is a prescription medicine that is used with other medications to treat partial-onset seizures with or without secondarily generalized seizures, and to treat primary generalized tonic-clonic (PGTC)...

Read More

FDA approves brain implant to help reduce Parkinson’s disease and essential tremor symptoms

June 12, 2015 — The U.S. Food and Drug Administration today approved the Brio Neurostimulation System, an implantable deep brain stimulation device to help reduce the symptoms of Parkinson’s disease and essential tremor, a movement disorder that is one of the most common causes of tremors. The Brio Neurostimulation System can help some patients when...

Read More

FDA advisory panel approves novel cholesterol-lowering drug

An advisory committee for the Food and Drug Administration has recommended the approval of a novel, injectable cholesterol-lowering drug called alirocumab, though many committee members have noted certain restrictions for its use and have requested further data on the drug’s ability to reduce the risk of heart problems. According to the Centers for Disease Control...

Read More

Alectinib approved by FDA for ALK-positive lung cancer

Alectinib, a new drug for anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer, has been approved by the US Food and Drug Administration (FDA).Alectinib, marketed as Alecensa by Genentech, has been licensed for patients who cannot tolerate crizotinib or whose disease has worsened after treatment with the drug.Alectinib was studied in two trials involving...

Read More

FDA approves Treatment for: Irritable Bowel Syndrome with Diarrhea (IBS-D)

Viberzi Generic Name: eluxadolineDate of Approval: May 27, 2015Company: Actavis plc Treatment for: Irritable Bowel Syndrome with Diarrhea (IBS-D) Viberzi is a first in class treatment for irritable bowel syndrome with diarrhea, treating the characteristic symptoms of abdominal pain and diarrhea. The U.S. Food and Drug Administration (FDA) has approved Viberzi...

Read More